Royalty Report: Drugs, Alzheimer’s disease, Disease – Collection: 262864

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Alzheimer’s disease
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Diagnostic
  • Drug Discovery
  • Biotechnology
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 262864

License Grant
Under the collaboration agreement, the German Company grants the partner an exclusive license to certain therapeutic antibodies for specific targets and receives license fees, research and development funding, milestone payments and/or, if a product is approved for marketing, sales royalties in return.  Through the Partnered Discovery Program, the Company generates antibody candidates for partners in the pharmaceutical and biotechnology industries. A HuCAL antibody targeting amyloid beta that is in phase 3 clinical testing by our partner for the treatment of Alzheimer’s disease is Gantenerumab.
License Property
Gantenerumab is a HuCAL antibody directed against amyloid beta (Aß) that is being developed for the treatment of Alzheimer’s disease. Aß denotes a group of peptides that are crucially involved in Alzheimer’s disease as the main component of the amyloid plaques found in the brains of Alzheimer’s patients. In phase 1 clinical trials, gantenerumab has been shown to reduce brain amyloid in mild-to-moderate Alzheimer’s disease patients. Gantenerumab is being investigated in several clinical studies to see if there is a positive effect from intervening at an early stage in the disease’s progression.
Field of Use
Gantenerumab is an investigational immunotherapy being developed to treat Alzheimer’s disease by potentially reducing beta-amyloid plaques in the brain.

IPSCIO Record ID: 26285

License Grant
The Licensor and the Licensee entered into a non-exclusive License Agreement  under the Licensor's patents. The Licensor has a know-how royalty on solanezumab which extends beyond the expiration of the patents. This is because the Licensor helped to design solanezumab.
License Property
Solanezumab is an experimental, humanized monoclonal antibody that binds to beta-amyloid. It is being studied as a potential therapy to delay the progression of Alzheimer’s disease.
Field of Use
The Licensee currently holds a license to the Queen et al patents with respect to solanezumab, its humanized antibody to beta amyloid which is currently being studied to delay the progression of Alzheimer’s disease.

IPSCIO Record ID: 125020

License Grant
University granted the Company a royalty bearing, exclusive worldwide license, limited to the field of Alzheimer’s Immunotherapy and Diagnostics.
License Property
United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use”, filed April 7, 2009 and granted May 29, 2012.
Field of Use
This agreement pertains to the drug industry relating to Alzheimer's Immunotherapy and Diagnostics.

IPSCIO Record ID: 266151

License Grant
The Company entered into a Research Grant and License Agreement with an Undisclosed Stockholder of the Company. The Agreement requires the Company to pay royalties to the stockholder.
License Property
The Company’s lead compound, COR388, is beginning Phase 2/3 development, targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models.  The compound is being developed for treatment of Alzheimers Disease.
Field of Use
This agreement pertains to the drug industry.  The IP will be used to try and create a disease-modifying therapeutic approach to Alzheimer’s and other degenerative diseases.

IPSCIO Record ID: 291176

License Grant
University hereby grants to Licensee and Licensee hereby accepts from University the License. University reserves the right to use, and to permit other non-commercial entities to use, the Research Technology for educational and research purposes other than conducting clinical trials. No license is granted to Licensee outside of the Field. The parties acknowledge that the United States government retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States.  

License shall mean the exclusive worldwide license to practice the Research Technology (as hereinafter defined) for the development, manufacture, use and sale of the Licensed Products (as hereinafter defined) in the Field.

License Property
Licensed Products shall mean any vaccine for the mitigation, prophylaxis or treatment of Alzheimer’s Disease, covered by a claim of any unexpired University Patent (as hereinafter defined) which has not been disclaimed or held invalid by a court of competent jurisdiction from which no appeal can be taken, or which incorporates or is developed using University Know-How.

University Patents shall mean all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor

(1)  
which claim Pre-Existing Inventions and which are identified on hereto; or

(2)  
which claim inventions that are made, in whole or in part, by students or employees of University during the term and in the course of the University Research Project.
6,713,450 – Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits

University Research Project shall mean the investigations at University during the Research Period (as hereinafter defined) into the Field under the supervision of the University Scientist(s) in accordance with the research program, which forms an integral part hereof.

Research Technology shall mean all University Patents and University Know-How.

Field of Use
Field shall mean the prophylaxis, mitigation and/or treatment of Alzheimer’s Disease.

IPSCIO Record ID: 362534

License Grant
For the Option, Licensor grants an irrevocable option, to be exercised at Licensee’s sole unfettered discretion, to acquire the license described.  The Option may be exercised any time from the Effective Date until March 31, 2009.

For the Grant of License, Licensor grants, commencing immediately upon exercise of the Option and for the term of this Agreement, a non-exclusive license under the Licensed Patents, with the right to grant sublicenses, to develop, have developed, make, have made, use, offer to sell, sell, import and have imported Licensed Products in the Territory in the Field.

License Property
Licensor is the owner of the Licensed Patents for DNA Encoding Recombinant Antibody Molecules End-Specific For Amyloid – B  Peptides, and, Pharmaceutical Compositions Thereof and Method of Preventing or Inhibiting Progression of Alzheimers Disease.

Lead Compound means Licensees antibody directed toward Amyloid Beta, commonly referred to within Licensee xx-04360365

Licensed Product means any product in any dosage form containing the licensed Pfizer Compound, the development, manufacture, use, sale or importation of which product would, absent the license granted by Licensor to Licensee herein, infringe any Valid Claim in any Licensed Patent.

Pfizer Compound means any antibody owned or licensed by Licensee or an Affiliate directed towards Amyloid Beta, including the Lead Compound.

Field of Use
The Field shall mean the treatment, prevention and/or control of all diseases and/or conditions in humans, including but not limited to Alzheimer’s Disease and Mild Cognitive Impairment.

IPSCIO Record ID: 362501

License Grant
For the Option. Licensor grants to the Licensee of England an irrevocable option, to be exercised at Licensees sole discretion, to acquire the license described.

For the Grant of License. when Licensee exercises the option, Licensor grants, commencing immediately upon exercise of the Option and for the term of this Agreement, a non-exclusive, license under the Licensed Patents, with the right to grant sublicenses, to develop, have developed, make, have made, use, offer to sell, sell, import and have imported Licensed Products in the Territory in the Field.

License Property
Licensor is the owner of the Licensed Patents for DNA Encoding Recombinant Antibody Molecules End Specific For Amyloid B Peptides, and, Pharmaceutical Preparations Thereof and Method of Preventing or Inhibiting Progression of Alzheimers Disease.

Licensees Compound means any compound, including but not limited to an antibody directed towards Beta Amyloid.

Licensed Product means any product in any dosage form, the development, manufacture, use, sale or importation of which product would, absent the grant by Licensor to Licensee of the license described herein, infringe any Valid Claim in any Licensed Patent. To avoid any doubt, Licensed Product shall include, without limitation, the Licensees Antibody currently under development for treatment of Alzheimers disease, designated x-933776A

Field of Use
Field means the treatment, prevention and/or control of all diseases and/or conditions in humans, including but not limited to Alzheimers and Mild Cognitive Impairment.

IPSCIO Record ID: 29371

License Grant
The Licensee has a worldwide exclusive License to intellectual property relating to ELND005 (AZD-103) with the undisclosed Licensor, an Alzheimer’s disease researcher at the University of Toronto.
License Property
ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for Alzheimer's disease (AD). ELND005 may prevent or inhibit the build up of amyloidal protein in the brains of Alzheimer's disease patients.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 27552

License Grant
University has granted diagnostic rights to certain knowhow and patent rights relating to Alzheimer's Disease.

This Agreement initially contemplates a transfer of existing Alzheimer Therapeutic Know-how to Licensee. Pursuant to such initial transfer and continuing collaboration thereafter, it is contemplated that Licensee will determine the amino add sequence of proteins and base sequence of nucleic acids, generate monoclonal antibodies, done and express and assess biological and therapeutic activity of proteins, all related to the Field of this Agreement.

In addition, Licensee will engage in a collaborative research project directed to the Field and funded by Licensee, which collaboration is contemplated to include
a.  development by Licensee of therapeutics based on specific materials provided; and
b.  other related research and development related to the development by Licensee of therapeutics for Alzheimer's disease.

Field of Use
The field of use is therapeutics for Alzheimer's disease and precursor or related conditions, including any applications in other neurodegenerative diseases derived from the results of the research done under this Agreement.

IPSCIO Record ID: 274655

License Grant
The German University granted an exclusive license to the University’s patent that underlies the Lympro Test.
License Property
The LymPro Test® is an immune-based neurodiagnostic blood test originally developed as a diagnostic blood test for detection of Alzheimer’s disease.
Field of Use
The field of use is to develop and commercialize the LymPro Test® for the detection of Alzheimer’s disease.

IPSCIO Record ID: 3499

License Grant
A Swiss licensee and an Irish licensor announced a worldwide, exclusive collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002. The license is granting rights to develop, make, have made, use, sell, offer to sell, import, and export the Licensed Products. Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.

Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.

License Property
PRX002 is a monoclonal antibody for the treatment of Parkinsons disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinsons disease in 2014.  

Synuclein proteins are a family of charged proteins found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies.

Field of Use
The rights granted apply to the medical industry.  Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.

IPSCIO Record ID: 203273

License Grant
Licensor hereby grants Licensees of the Netherlands and Ireland, an exclusive, even as to Licensor, license, with the right to grant sublicenses, under the Licensed Patents to research, develop, use, have used, make, have made, offer for sale, sell, have sold, import and export Bapineuzumab Products in the Field in the Territory.

Licensor hereby grants each Licensee a non-exclusive license, with the right to grant sublicenses, under the Licensed Patents to research, develop, use, have used, make, have made, offer for sale, sell, have sold, import and export Licensed Products other than Bapineuzumab Products in the Field in the Territory.

License Property
Licensed Products shall mean any therapeutic, prophylactic and/or diagnostic product, the composition, manufacture or use of which would, but for the licenses granted by Licensor to Licensees herein, infringe a Valid Claim of a Licensed Patent owned or otherwise Controlled by Licensor.

The patents relate to DNA Encoding Recombinant Antibody Molecules End Specific for Amyloid ß Peptide.

Aß Peptide shall mean P-amyloid protein which is the cleavage product of amyloid precursor protein, occurring predominantly as a (1-39) to (1-43) amino acid.

Field of Use
Field shall mean the treatment, prevention and/or diagnosis of diseases and/or conditions in humans, including but not limited to Alzheimers Disease  and Mild Cognitive Impairment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.